NASDAQ:BLU
Delisted

Bellus Health Stock Insider Trading

etoro logo Buy BLU
*Your capital is at risk
$14.74
+0 (+0%)
At Close: Sep 27, 2023

Bellus Health Stock Insider Power

Based on the 0 latest insides trades, we have calculated the insider power to be negative at 0. In total, the insiders bought 0 and sold 0 BLU shares in the last 0 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Historical Insider Trades

There is currently no insider trading information for this ticker.

However, we invite you to learn more about this term and how to use this knowledge to benefit your trading strategy:

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

Click to get the best stock tips daily for free!
ABOUT BELLUS HEALTH INC.
Bellus Health
BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada....
GOLDEN STAR
Ticker Change Signal Date
EAT
$140.46
7.38% Jun 05
TPR
$140.47
3.67% Jun 04
N
NVRI
$19.53
8.19% May 20
SAP
$172.39
3.79% May 05
GLBE
$31.61
2.44% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE